Oncolytics completes enrollment in phase 1 trial of Reolysin

New York, June 15 - Oncolytics Biotech Inc. said it completed enrollment in the dose escalation portion of its U.K. phase 1 systemic administration clinical trial investigating the use of Reolysin to treat patients with advanced cancers.

A total of 30 patients were treated in the trial at escalating frequency and dosage to a maximum daily dose of 1x10(11) TCID(50). A maximum tolerated dose was not reached and the treatment appears to have been well tolerated by the patients, the company said.

The primary objective of the trial is to determine the maximum tolerated dose, dose limiting toxicity and safety profile of Reolysin. A secondary objective is to examine any evidence of anti-tumor activity.

Eligible patients include those who had been diagnosed with advanced or metastatic solid tumors that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

Oncolytics is a Calgary, Alta.-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.